Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells $1,149,737.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 58,750 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $19.57, for a total transaction of $1,149,737.50. Following the completion of the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at $12,332,348.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Melissa Baird also recently made the following trade(s):

• On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total transaction of $172,122.85.
• On Tuesday, August 6th, Melissa Baird sold 16,784 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.00, for a total transaction of $285,328.00.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $17.84 on Friday. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a fifty day moving average price of $16.38 and a 200-day moving average price of $17.34. The company has a market cap of $3.83 billion, a price-to-earnings ratio of -1,784.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the subject of several research analyst reports. TD Cowen raised their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Bank of America lowered their target price on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday, September 13th. Finally, Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average target price of $19.86.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its stake in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares in the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. CWM LLC lifted its stake in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank lifted its stake in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.